PBS Biotech® Launches Single-Use Bioreactor for Development of New Vaccines and Biosimilars
Benchtop size, easy-to-use, plug and play bioreactor using advanced Air-Wheel® mixing technology reduces cost and time to market
The PBS 3 is a fully integrated and pre-configured system with powerful process control capability in one-third the size and weight of competing systems. The benchtop unit can be installed by a single operator within minutes and securely monitored or controlled using the touch screen or remotely by computer or smart phone, including an iPhone® or iPad®, over a secured Internet or Ethernet connection. The disposable vessel is constructed of USP Class VI plastic to meet the cGMP regulatory requirements. Key product features include the Air-Wheel™ mixing mechanism, proprietary auto sampler system, and user-friendly graphical interface of the controller.
“Our PBS 3 liter system is the most advanced laboratory scale, single-use bioreactors in the industry and is the first in our family of products. The bioreactor’s innovative, ease-of-use, and compact design will provide unique benefits and value to customers who want to gain operational efficiency and flexibility for reduced developmental cost and time,” said Dr. Brian Lee, co-founder and president of PBS Biotech and former senior scientist at leading biopharmaceutical companies Amgen and Merck & Co.
“We are grateful for the support of our Advisory Board and the dedication of our product development team for their time and inspired ideas in creating the most advanced single-use bioreactors,” Dr. Lee added. PBS Biotech boasts pre-launch product trials and evaluations in numerous biotech and academic research organizations in North America, Europe, and Asia.
“The PBS 3 single-use bioreactor leads the way for scientists to upgrade existing equipment by adopting an entry level platform that is fully scalable from lab to production stages. We are particularly encouraged by the value proposition that we deliver for global biosimilar companies entering the market,” said James B. Schultz, VP of Sales and Marketing.
Biosimilars are generic biological drugs that are similar to the original branded products. The market for these generic products is expected to grow from $250 million today to over $4 billion by 2014 globally. Production of biosimilar products is extremely cost sensitive and requires significant operational efficiency and flexibility, which can be benefited from broader and immediate adoption of single-use bioreactors and related disposable products.
About PBS Biotech
PBS Biotech, Inc. is a U.S. corporation headquartered in Camarillo, California that manufactures fully scalable and easy-to-use single-use bioreactors for global biotechnology organizations. The company has developed innovative, efficient, and scalable bioreactors by combining a patented pneumatic mixing mechanism with an advanced, proprietary control system. This novel bioreactor solution offers improved operational efficiency and flexibility with reduced costs and ultimately shorter time to market for biotechnology customers. PBS Biotech is poised for rapid growth by supporting industry demand for single-use technologies.
Contact: Rick Sullivan, VP Sales & Marketing